The present invention relates to solid state forms of 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione hydrochloride compound of formula-1a and their processes for the preparation thereof and an improved process for the preparation of 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione hydrochloride.
The present inventors also provides an amorphous polymorph of the combination drug consisting of 2′-deoxy-5-(trifluoromethyl) uridine and 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione monohydrochloride and its process for the preparation.
本发明涉及固态形式的5-
氯-6-[(2-亚
氨基
吡咯烷-1-基)甲基]
嘧啶-2,4-(1H,3H)-二酮盐酸盐式-1a化合物及其制备工艺,以及制备5-
氯-6-[(2-亚
氨基
吡咯烷-1-基)甲基]
嘧啶-2,4-(1H,3H)-二酮盐酸盐的改进工艺。
本发明人还提供了一种由 2′-脱氧-5-(三
氟甲基)
尿苷和 5-
氯-6-[(2-亚
氨基
吡咯烷-1-基)甲基]
嘧啶-2,4-(1H,3H)-二酮组成的复方药物的无定形多晶型盐酸盐及其制备工艺。